CA
NZ
UK
AU
IND
US
…
Getinge AB (publ) provides products and solutions for operating rooms, intensive-care units, and sterilization departments in Sweden and internationally. The company operates through Acute Care Therapies, Life Science, and Surgical Workflows segments. It offers extracorporeal membrane oxygenation, mechanical ventilation, advanced patient monitoring, ICU infrastructure equipment, and drainage solutions. In addition, the company provides surgical perfusion, endoscopic vessel harvesting, intra-aortic balloon counterpulsation, vascular and cardiothoracic surgery equipment, peripheral stenting, OEM solutions, and beating heart surgery equipment; and operating room equipment, anesthesia, advanced patient monitoring, and operating room integration solutions. Further, it offers pre-cleaning, cleaning and disinfection, sterilization, consumables, endoscope reprocessing, and sterile supply management solutions; connected medical devices, and patient flow management; and low temperature sterilization, biocontainment in vaccine production, terminal sterilization, sterile isolation technology, cleaning and sterilization, aseptic transfer, and large-scale cultivation. Additionally, the company provides bioreactor preparation solution, bioprocess development and optimization, labware cleaning and sterilization, biocontainment, and vivarium. It offers its products through a network of sales companies, as well as through agents and distributors in the Americas, Europe, the Middle East, Africa, and the Asia and Pacific. Getinge AB (publ) was founded in 1904 and is headquartered in Gothenburg, Sweden.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
Getinge Industrier AB is a Swedish medical-technology company supplying equipment and services for operating rooms, intensive care and infection control and serving hospitals and life-science customers globally. Long-term growth could be supported by demographic-driven demand, rising healthcare spending and recurring aftermarket services and consumables. Its broad product portfolio and installed-service network appears positioned to benefit from secular healthcare trends.
Investors should monitor regulatory and product-liability exposure, reimbursement and hospital capital-spending cyclicality, competitive and execution risk, and supply-chain and currency volatility.
Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Income before tax | 3145.00M | 2282.00M | 3343.00M | 3472.00M | 4188.00M |
| Minority interest | -17.00M | -16.00M | -20.00M | -25.00M | -31.00M |
| Net income | 2258.00M | 1638.00M | 2412.00M | 2491.00M | 2970.00M |
| Selling general administrative | 4182.00M | 4240.00M | 4315.00M | 3516.00M | 3337.00M |
| Selling and marketing expenses | 5345.00M | 5354.00M | 5366.00M | 4870.00M | 4590.00M |
| Gross profit | 16654.00M | 16153.00M | 14495.00M | 13409.00M | 13580.00M |
| Reconciled depreciation | 2250.00M | 2421.00M | 2185.00M | 2027.00M | 1814.00M |
| Ebit | 4186.00M | 2888.00M | 3812.00M | 3626.00M | 4371.00M |
| Ebitda | 6436.00M | 5309.00M | 5905.00M | 5939.00M | 6168.00M |
| Depreciation and amortization | 2250.00M | 2421.00M | 2093.00M | 2313.00M | 1797.00M |
| Operating income | 3789.00M | 2854.00M | 3736.00M | 3626.00M | 4371.00M |
| Other operating expenses | 31180.00M | 31905.00M | 28091.00M | 24409.00M | 22783.00M |
| Interest expense | 484.09M | 606.00M | 469.00M | 205.00M | 152.00M |
| Tax provision | 869.00M | 628.00M | 868.00M | 956.00M | 1187.00M |
| Interest income | 73.00M | 68.00M | 123.00M | 54.00M | 10.00M |
| Net interest income | -644.00M | -571.00M | -308.00M | -174.00M | -183.00M |
| Income tax expense | 869.00M | 628.00M | 915.00M | 956.00M | 1187.00M |
| Total revenue | 34969.00M | 34759.00M | 31827.00M | 28291.00M | 27049.00M |
| Total operating expenses | 12865.00M | 13299.00M | 10759.00M | 9527.00M | 9314.00M |
| Cost of revenue | 18315.00M | 18606.00M | 17332.00M | 14882.00M | 13469.00M |
| Total other income expense net | -644.00M | -572.00M | -393.00M | -154.00M | -183.00M |
| Net income from continuing ops | 2276.00M | 1654.00M | 2271.00M | 2516.00M | 3001.00M |
| Net income applicable to common shares | - | - | - | - | 2970.00M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Total assets | 56505.00M | 63918.00M | 53586.00M | 52032.00M | 44555.00M |
| Intangible assets | 7738.13M | 9153.00M | 2846.00M | 4497.00M | 4467.00M |
| Other current assets | - | 360.00M | 1138.00M | 1.00M | -1.00M |
| Total liab | 27012.00M | 30708.00M | 23183.00M | 21579.00M | 19379.00M |
| Total stockholder equity | 29429.00M | 33005.00M | 30166.00M | 30038.00M | 24749.00M |
| Deferred long term liab | - | - | - | - | 2763.00M |
| Other current liab | 8962.00M | 9758.00M | 4874.00M | 8948.00M | 476.00M |
| Common stock | 136.00M | 136.00M | 136.00M | 136.00M | 136.00M |
| Capital stock | 136.00M | 136.00M | 136.00M | 136.00M | 136.00M |
| Retained earnings | 21504.00M | 20328.00M | 19861.00M | 18796.00M | 16579.00M |
| Other liab | - | - | - | - | 5273.00M |
| Good will | 25775.45M | 30088.00M | 24869.00M | 22514.00M | 19681.00M |
| Other assets | - | -1.00M | - | - | 3981.00M |
| Cash | 3401.00M | 2961.00M | 2728.00M | 5676.00M | 4076.00M |
| Total current liabilities | 13042.00M | 15047.00M | 13185.00M | 11993.00M | 10610.00M |
| Current deferred revenue | - | - | 2453.00M | - | 7402.00M |
| Net debt | 7483.00M | 7766.00M | 5348.00M | 148.00M | 230.00M |
| Short term debt | 1962.00M | 2447.00M | 3116.00M | 793.00M | 811.00M |
| Short long term debt | 1510.00M | 1956.00M | 2694.00M | 410.00M | 475.00M |
| Short long term debt total | 10884.00M | 10727.00M | 8076.00M | 5824.00M | 4306.00M |
| Other stockholder equity | 7789.00M | 6789.00M | 10169.00M | 11106.00M | 8034.00M |
| Property plant equipment | - | - | - | - | 4120.00M |
| Total current assets | 17227.00M | 18162.00M | 16647.00M | 19106.00M | 15069.00M |
| Net tangible assets | - | - | - | - | 3365.00M |
| Short term investments | - | - | 60.00M | - | - |
| Net receivables | 7808.00M | 8251.00M | 6364.00M | 7197.00M | 6227.00M |
| Long term debt | 7893.00M | 6971.00M | 3903.00M | 4100.00M | 2795.00M |
| Inventory | 6018.00M | 6590.00M | 6416.00M | 6232.00M | 4767.00M |
| Accounts payable | 2118.00M | 2398.00M | 2355.00M | 2252.00M | 1921.00M |
| Accumulated other comprehensive income | - | 5752.00M | 3380.00M | - | - |
| Non currrent assets other | -0.00M | 34.00M | 3954.00M | 50.00M | -1.00M |
| Non current assets total | 39278.00M | 45757.00M | 36939.00M | 32926.00M | 29486.00M |
| Capital lease obligations | 1481.00M | 1800.00M | 1479.00M | 1314.00M | 1036.00M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Investments | - | -4549.00M | -1700.00M | -1470.00M | -1329.00M |
| Change to liabilities | - | - | - | - | 0.00M |
| Total cashflows from investing activities | -2782.37M | -4549.00M | -6543.00M | - | -1329.00M |
| Net borrowings | 1000.00M | 2207.00M | 2197.00M | - | -6378.00M |
| Total cash from financing activities | -719.09M | 504.00M | 511.00M | -500.00M | -7237.00M |
| Change to operating activities | - | - | - | - | 208.00M |
| Net income | 3789.00M | 2854.00M | 2412.00M | 3626.00M | 4371.00M |
| Change in cash | 952.24M | 233.00M | -2948.00M | 1600.00M | -1980.00M |
| Begin period cash flow | 2961.00M | 2728.00M | 5676.00M | 4076.00M | 6056.00M |
| End period cash flow | 3401.00M | 2961.00M | 2728.00M | 5676.00M | 4076.00M |
| Total cash from operating activities | 3712.96M | 4577.00M | 2957.00M | 3367.00M | 6560.00M |
| Depreciation | 2250.00M | 2421.00M | 2093.00M | 2027.00M | 1814.00M |
| Other cashflows from investing activities | 194.63M | 16.00M | -776.00M | - | 316.00M |
| Dividends paid | 1177.81M | 1227.00M | 1158.00M | -1111.00M | -858.00M |
| Change to inventory | -465.00M | 46.00M | -202.00M | -998.00M | -71.00M |
| Change to account receivables | -218.00M | -712.00M | -305.00M | - | 805.00M |
| Other cashflows from financing activities | -541.28M | -476.00M | -52.00M | 1052.00M | 780.00M |
| Change to netincome | - | - | - | - | 841.00M |
| Capital expenditures | 1235.15M | 1309.00M | 1353.00M | 1136.00M | 930.00M |
| Change in working capital | -1187.00M | -416.00M | -1640.00M | -1242.00M | 942.00M |
| Other non cash items | -1139.04M | -282.00M | 92.00M | -1044.00M | -567.00M |
| Free cash flow | 2477.81M | 3268.00M | 1604.00M | 2231.00M | 5630.00M |
Sector: Healthcare Industry: Medical Devices
|
Stock Name
|
Change
(USD) |
Price
(USD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to Revenue (x) |
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| GNGBY Getinge Industrier AB |
- -% |
28.11 | 24.19 | 17.42 | 1.88 | 2.08 | 2.16 | 11.79 |
| ABT Abbott Laboratories |
0.24 0.22% |
110.75 | 25.97 | 17.24 | 3.57 | 3.20 | 3.81 | 16.75 |
| MDT Medtronic PLC |
-1.20 1.17% |
101.59 | 26.60 | 15.87 | 3.35 | 2.08 | 3.90 | 14.12 |
| SYK Stryker Corporation |
-1.51 0.46% |
324.22 | 29.23 | 16.86 | 4.18 | 4.51 | 4.63 | 17.16 |
| SEMHF Siemens Healthineers AG |
-0.98 1.99% |
48.27 | 39.57 | 21.32 | 3.01 | 3.29 | 2.95 | 16.92 |
Getinge AB (publ) provides products and solutions for operating rooms, intensive-care units, and sterilization departments in Sweden and internationally. The company operates through Acute Care Therapies, Life Science, and Surgical Workflows segments. It offers extracorporeal membrane oxygenation, mechanical ventilation, advanced patient monitoring, ICU infrastructure equipment, and drainage solutions. In addition, the company provides surgical perfusion, endoscopic vessel harvesting, intra-aortic balloon counterpulsation, vascular and cardiothoracic surgery equipment, peripheral stenting, OEM solutions, and beating heart surgery equipment; and operating room equipment, anesthesia, advanced patient monitoring, and operating room integration solutions. Further, it offers pre-cleaning, cleaning and disinfection, sterilization, consumables, endoscope reprocessing, and sterile supply management solutions; connected medical devices, and patient flow management; and low temperature sterilization, biocontainment in vaccine production, terminal sterilization, sterile isolation technology, cleaning and sterilization, aseptic transfer, and large-scale cultivation. Additionally, the company provides bioreactor preparation solution, bioprocess development and optimization, labware cleaning and sterilization, biocontainment, and vivarium. It offers its products through a network of sales companies, as well as through agents and distributors in the Americas, Europe, the Middle East, Africa, and the Asia and Pacific. Getinge AB (publ) was founded in 1904 and is headquartered in Gothenburg, Sweden.
| Name | Title | Year Born |
|---|---|---|
| Mr. Mattias Perjos M.Sc. | CEO, Pres & Director | 1972 |
| Mr. Lars Sandstrom M.Sc. | Chief Financial Officer | 1972 |
| Mr. Lars Mattsson | Head of Investor Relations | NA |
| Ms. Anna Romberg MSc Econ | Exec. VP of Legal, Compliance & Governance | 1979 |
| Ms. Jeanette Heden Carlsson | Exec. VP of Communications & Brand Management | 1966 |
| Mr. Magnus Lundback Ph.D. | Exec. VP of HR & Sustainability | 1969 |
| Dr. Dieter Engel | Chief Technology Officer of Surgical Workflows | NA |
| Mr. Carsten Blecker | Chief Commercial Officer | 1966 |
| Mr. Stephane Le Roy | Pres of Surgical Workflows | 1977 |
| Ralf Uwe Schmit | Corp. Head of Sustainability | NA |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.
Download a free report with stock ideas and industry insights for general information.
Download Free Report Now →
Basic Materials
-1.26%
Communication Services
-0.18%
Consumer Cyclical
-0.36%
Consumer Defensive
+0.07%
Energy
-0.01%
Financial Services
-0.26%
Financials
-2.20%
Healthcare
-0.55%
Industrials
-0.08%
Real Estate
-0.33%
Technology
-0.70%
Utilities
-0.41%
Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.
Portfolio
Watchlist
Please wait processing your request...